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target populations; 3) the need for fast, iterative assessments of technologies from 
development to implementation stages; 4) the need for ready available repositories 
of (country-specific) epidemiology and cost data; and 5) the need to extrapolate 
results over time and settings. To address these challenges, the Joint Research Center 
(JRC) of the European Commission has commissioned the construction of an online 
tool that allows stakeholders of the EIP on AHA to estimate the health economic 
impact of their interventions in real-time. At the core of this tool is a generic, highly 
adaptable Markov model with three mutually exclusive health states (‘baseline 
health’, ‘deteriorated health’ and ‘death’), combined with an extensive database of 
epidemiological, economic and effectiveness data. The tool assesses the impact of 
an innovation on resource use (both from a healthcare and societal perspective) and 
the Health Related Quality of Life of patients. We demonstrate the application and 
discuss the value of the tool using a case study from the EIP on AHA, on the develop-
ment of a falls prediction device. An early assessment (prior to clinical testing) was 
performed to estimate the possible impact of this intervention, considering various 
implementation scenarios. Finally, we will discuss the conceptual and practical nov-
elty as well as the (scientific) challenges of this approach for informing healthcare 
decisions regarding research funding, innovation development and implementation.
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Objectives: Capturing QOL information in orphan indications presents multiple 
barriers. Patient recruitment is challenging due to low incidence and severity 
of the condition. An additional consideration is the inability to make statistical 
inference due to low sample sizes. Outcomes research teams must consider novel 
methods for optimizing data collection and analysis within these populations. This 
case study evaluates the methods to address QOL data gaps in RR-DTC, a hard-to-
treat, rare cancer. MethOds: In a real-world observational study of patients with 
RR-DTC, a mixed-methods quantitative survey and qualitative data collection is 
being conducted to ascertain direct patient feedback through survey data collection 
and patient interviews. Sampling of patients is being done from the target popu-
lation in a real-world setting. This mixed-methods approach allows for an all-
encompassing understanding of the patient’s treatment experience and relevance 
of qualitative change to quantitative reporting within the clinical trial. Study docu-
ments capture symptoms and impact data cross-sectionally and longitudinally 
and to allow for the cross-linking of survey results to the clinical data. Results: 
Data will be presented on a sample of 120 patients: 50 currently undergoing sys-
temic therapy with sorafenib, 50 with lenvatinib, and 20 receiving no systemic 
therapy. QOL endpoints include the Functional Assessment of Cancer Therapy-
General (FACT-G), EQ-5D-5L, Symptoms & Toxicities experience, Impressions of 
Treatment Satisfaction, and Subject Preference. In addition, data from qualita-
tive interview of 40 patients will be presented to fully conceptualize quality of 
survival. The methods for patient recruitment and barriers to implementation 
will be presented as well as mixed methodology for interpreting quantitative 
survey data using supportive qualitative information. cOnclusiOns: In absence 
of phase 3 QOL data in rare indications, a mixed-method approach utilizing real-
word observational study can yield important information that supports previ-
ously demonstrated survival benefit and help our understanding of treatment 
impact on quality of survival.
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Objectives: Drug authorization in Germany is regulated by the early benefit assess-
ment based on the risk-benefit ratio according to IQWiG General Methods. For con-
sumer goods, the Federal Institute for Risk Assessment (BfR) evaluates the risk by 
quantifying potential hazards and the exposure. Investigation regarding the gap 
between the assessments has rarely been done. This article aims to give a profound 
understanding of the concepts from IQWiG and BfR, and an initial recommendation 
to fill the gap. MethOds: The IQWiG General Methods and the BfR guidance for 
risk assessment are reviewed to compare their frameworks and evidence stand-
ards. Based on the results of the comparison, a product Xthat fits the gap between 
drugs and consumer goods is simulated and methods that fills the gap are recom-
mended. Results: Risk/Benefit assessment according to IQWiG is rigorously based 
on the Evidence Based Medicine (EBM) standards, while risk assessment accord-
ing to BfR has a clear focus on transparency of research. Risk/benefit according to 
IQWiG is assessed via patient-relevant endpoints, which is not applicable to the risk 
assessment of most consumer goods according to BfR. Recommendations for the 
simulated product Xinclude the adaption of the evidence standard, re-definition 
of risk and benefit and the application of mathematical models. cOnclusiOns: 
Various gaps exist between risk/benefit assessment for drugs and risk assessment 
for consumer goods. As more and more emerging products are waiting for the mar-
ket launch, a new guidance that fills the gap and is applicable for these products 
would be highly necessary.
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Pharmaceutical sponsors strive to capture the patient voice during drug develop-
ment. One emerging trend is the role that patient advocates can play in influencing 
regulatory decision making, often through powerful and emotive testimonials at 
the ‘probabilistic sensitivity analysis’ sample: a single set of samples from the model 
parameters, along with the corresponding modelled costs and health outcomes. 
The only extra requirement for EVSI is the ability to simulate study data. There is 
no need to re-run the model in either case. We have made available an easy-to-use, 
open access, web-based Value of Information calculator called ‘SAVI’ http://savi.shef.
ac.uk/SAVI. CONCLUSION: Value of Information measures can now be computed 
quickly for models of any complexity, and hence be made more widely available to 
modellers and decision makers.
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Objectives: Detailed data on type 2 diabetes mellitus (T2DM) patients and treat-
ment in clinical practice are scarce. The Nordic region offers unique opportunities 
for research on patient-level data from various complementary data sources, by 
availability of homogenous public healthcare systems with clinical information 
registered in electronic medical records (EMR) and mandatory national registers, and 
data linkage using the unique personal identification numbers for all inhabitants. 
This paper describes the implementation of a novel research methodology utilized 
in the Nordic countries to provide new T2DM insights based on a hybrid utilization of 
EMR data combined with national health registers, and supports the ongoing global 
DISCOVER program (NCT02322762). MethOds: This observational study collects 
both prospective health care data and retrospective longitudinal data. Patient-level 
information (e.g. demographics, diagnoses, clinical notes, laboratory results, health 
care contacts and referrals) of the enrolled T2DM patients will be extracted from EMR 
at each study site. To facilitate clinical data completeness, specific variables will be 
collected by electronic case report forms. In addition, the national full population 
registers (patient-, cause of death- and prescribed drug registers) provide longitudi-
nal data for the enrolled T2DM patients, the complete study site T2DM cohorts, and 
the nationwide full T2DM population. Results: This approach, bridging data from 
the enrolled T2DM patients, the complete cohort of T2DM patients at the study sites, 
and the nationwide full population, generates extended observational data with 
high internal and external validity from approximately 1 million T2DM patients. 
Iterative data collection spanning several years (2015 – 2018), thus potentiating 
interim analyses, will provide contemporary insights of T2DM disease progression 
and treatment development. cOnclusiOns: This novel methodology presents a 
new era for observational research, providing efficient ways of generating com-
prehensive data with high completeness and minimal interference with ordinary 
clinical practice. This is highly relevant for diabetes and other chronic diseases.
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bAckgROund: What distinguishes informative health outcomes from all other 
measures of health is whether these are based on the perception and preferences 
of patients. New HRQoL preference-based measurement methods that use the 
patient’s own evaluations as the point of reference (patient-centered) seems essen-
tial. existing problems All existing generic preference-based HRQoL instruments 
(e.g. EQ-5D, HUI, SF-6D) use a small, fixed set of health attributes, forming descrip-
tions of health states that are valued by samples of the general population. When 
developing those instruments, patients’ opinions were not actively incorporated in 
the choice of attributes, nor have patients’ preferences been considered in assessing 
weights to the attributes. Compelling arguments against the currently dominant val-
uation technique, the time trade-off, have been raised by several authors. For these 
reasons, the existing instruments seem to lack credibility. an improved approach We 
developed a completely novel preference-based HRQoL measurement instrument 
that combines the strength of two existing measurement models: discrete choice 
modeling and Rasch item response theory. It is referred to as the multi-attribute 
preference response (MAPR) model. The response mechanism of the MAPR model 
is insensitive to various biases (e.g., adaptation, time preference, indifference pro-
cedure). Moreover, this is the first generic HRQoL preference-based model that is 
fully based on the perception and reporting from patients. The response task for the 
patient is to judge whether a hypothetical health-state description is considered to 
be worse or better than the health condition of the patient himself. Apart from being 
grounded on measurement theory, the tasks are easy and attractive to perform in 
a self-completion setting. Conclusion After years of dominance of ad hoc methods 
to derive values for patients’ health conditions, we present an informative HRQoL 
measurement model that overcomes credibility problems facing the conventional 
instruments.
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On European and national levels substantial investments are done in partnerships 
that aim to stimulate the development and implementation of healthcare innova-
tions. One such partnership is the European Innovation Partnership on Active and 
Healthy Ageing (EIP on AHA). Monitoring and assessing the societal, healthcare 
and patient impact of such large innovation partnerships is challenging for many 
reasons, including 1) the wide range of interventions developed; 2) the variety in 
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Objectives: To demonstrate the need to revise discount rates in the cost-effective-
ness analysis (CEA) methods guidelines in Belgium, the Netherlands, Poland and 
the UK. MethOds: We identify what discount rates are recommended in the CEA 
guidelines of the countries above and examine what rationale has been provided 
in each case. We assess the recommended guidelines in the context of the current 
theory and empirical evidence on discounting. Results: The UK requires discount-
ing of 3.5% for cost and effects in its basecase guidance, but also recommends 1.5% 
for public health interventions and for specific life-saving interventions. No ade-
quate justification has been provided for this disparity. Applying different discount 
rates for the same goal of achieving health gain from the same pool of resources is 
illogical and yields inefficient outcomes. Belgium, the Netherlands and Poland all 
recommend differential discounting of costs and effects. The discounting guidance 
in these countries pre-dates recent work that further clarifies the basis for differ-
ential discounting. This is significant, as this recent work shows how, under certain 
assumptions, the differential between costs and effects can be linked to growth in 
threshold. In turn, this may imply that the differential employed in these countries 
may be too great. Finally, assuming that the discount rate applied to costs should 
approximate government borrowing costs, it is likely that the cost discount rate is 
too high in the base case of all of the countries considered here. cOnclusiOns: 
The choice of discount rates is important as they are highly influential on the cost-
effectiveness of many interventions. Applying different discount rates to different 
interventions is not justified. Similarly, the rates applied in countries recommend-
ing differential discounting lack firm justification. Resource allocation in all the 
countries considered would likely be improved by the application of a lower com-
mon discount rate.
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Objectives: The clinical value of genomic tests is not always apparent, and very 
few have demonstrated cost-effectiveness. The objective of this conceptual paper 
is to understand whether the principles and methods of cost-effectiveness analy-
sis (CEA) are appropriate for the evaluation of genomic-based diagnostic tests, 
such as whole genome sequencing. MethOds: Literature on CEA methods to 
evaluate genomic tests was systematically searched using ‘pearl growing’ meth-
ods. Data were extracted to identify challenges and solutions to conducting CEA in 
this context. The key characteristics of genomic tests from an economic perspec-
tive were summarized and used to distinguish further challenges. Results: Our 
review highlights two main differences between CEA of genomic tests and that 
of other technologies: the complexities of evaluating tests for multiple disorders 
and the potential for genomic information to have consequences for future gen-
erations requiring infinite time horizons. Another common feature, not unique 
to genomic-based diagnostic tests but commonly identified in the literature, was 
the valuation of non-health benefits. Alternatives to evaluate the diagnosis of 
multiple disorders are discussed: an iterative approach assessing each diagnosis 
independently; an aggregate approach combining the cost and benefits from all 
disorders into a single evaluation; a pragmatic approach that identifies the most 
important disorders combined with a qualitative assessment of the direction of 
bias for disorders not included in the full analysis. Consideration of the potential 
for infinite time horizons suggests CEA should focus on systems that could store, 
and share, genomic information between generations. cOnclusiOns: The chal-
lenges shared with other health technologies, particularly diagnostic tests, suggest 
that the general principles and methods of CEA are appropriate for genomic tests. 
Further methodological research would be valuable on approaches for assess-
ing the value of sharing genomic information across generations, approaches 
to evaluate tests for multiple disorders and trading-off health and non-health 
benefits.
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Standard cost-effectiveness methods and critical appraisal toolkits may not be ade-
quate for complex interventions. We systematically reviewed and quality assessed 
cost-effectiveness studies of a complex intervention, propose a series of new ques-
tions to inform their critical appraisal and discuss how future research should be 
targeted to improve the methods. Reablement was used as an example of a complex 
intervention. Reablement is a multidisciplinary and multifactorial intervention to 
support people to relearn activities of daily living. The systematic review identi-
fied 12 cost-effectiveness studies on reablement, out of 3,311 unique records. The 
12 included studies were data extracted and quality evaluated using a standard 
checklist. No study provided enough information to inform the decision on whether 
reablement is cost-effective and should be reimbursed by the payer. The issues 
included: (i) the use of a perspective not relevant for the decision-maker, (ii) lack of 
consideration for inter-sectoral effects, (iii) short time horizon, (iv) poor descriptive 
detail on the interventions, (v) limited comparators, (vi) poor quality evidence on 
effectiveness, (vii) limited evaluation of uncertainty and (viii) no consideration of the 
panel hearings. In two recent highly publicised Food and Drug Administration advi-
sory panel recommendations for orkambi (cystic fibrosis; Vertex Pharmaceuticals) 
and flibanserin (hypoactive sexual desire disorder; Sprout Pharmaceuticals), tes-
timonials from patients involved in the trials appeared to play an important role 
in influencing positive recommendations. Feedback from patients participating 
in clinical trials can provide important information on the potential benefits of a 
drug beyond the clinical endpoints measured in a trial. However, critics suggest 
that the purposively selected patient testimonials used within these regulatory 
interactions are not sufficiently robust sources of data. The authors argue that 
patient testimonials which influence regulatory decision making should be con-
sidered as qualitative data and therefore appraised in-line with other qualitative 
data submitted as part of a new drug application e.g., qualitative data supporting 
content validity of patient-reported outcome measures. Testimonials are unlikely 
to be considered either credible or rigorous in their current format, particularly as 
samples are often heavily biased towards patients who have experienced positive 
outcomes whilst on the product. Patient interviews planned a priori can provide 
valuable insights on the efficacy of a new medication and other important factors 
such as tolerability and adherence. The authors propose a structured framework to 
eliciting and analysing these data through qualitative interviews ‘nested’ within 
clinical trials. The authors present a procedural checklist for ensuring that cred-
ible and robust data are collected. This includes ensuring representative sampling 
(e.g., patients on both treatment arms and with varying socio-demographic and 
clinical profiles), utilising trained qualitative interviewers experienced in quali-
tative data collection and analysis, and timing of interviews (e.g., during and/or 
after the clinical study).
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Objectives: Phase III trials typically exclude patients with certain baseline character-
istics, such as older age or co-morbidities, and thereby hamper learning of new drugs’ 
effectiveness in real-life. A simulation study was conducted to support implementa-
tion of new inclusion criteria for Phase 3 trials in schizophrenia without increasing 
sample size nor compromising detection of the new drug effect. MethOds: A simula-
tion study was performed examining the impact of re-introducing through stratifying 
by each of the following excluded patients population: age > 65 years, duration of 
illness < 3 years, patients with previous suicide attempts, patients with history of 
alcohol or substance abuse, and patients treated in private practices. Patients with 
these characteristics were multiplied in a synthetic trial population until their real-life 
proportion in schizophrenia was reached. The simulation used data subsets from the 
10,281-patient observational SOHO cohort study. A “base case RCT” was created by 
applying typical Phase 3 exclusion criteria. A series of “synthetic RCTs” were defined 
by replacing patients with SOHO patients that were initially excluded. The real-life 
drug effect was predicted from each synthetic RCT through regression models and 
compared with the real-life effect in SOHO. Results: Perhaps surprisingly, effects of 
all 3 investigated drugs were found to be larger in real-life than in the base case RCT. 
Synthetic RCTs were created by replacing patients of the base RCT with patients with 
a given baseline characteristic. Prediction of real-life effects improved with increasing 
replacement in terms of mean squared prediction errors and coverage of confidence 
interval. However, the impact of introducing these “real-life” populations was not 
equal among factors. For instance, introducing older patients minimally improved 
prediction of real-life effects, while allowing inclusion of just 5% of patients with 
past suicide attempts (who make up 25% of the real-life schizophrenia population) 
significantly improved effectiveness predictions.
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Objectives: Develop a method to quickly test whether a network meta-analysis 
evidence network is connected. BACKGROUND Network meta-analysis, or mixed 
treatment comparisons, is a method to combine evidence on multiple treatments 
that have been compared in randomised controlled trials that form a connected 
network of treatment comparisons. Evidence networks consist of nodes, repre-
senting treatments, and edges, representing clinical trials comparing two treat-
ments. If nodes corresponding to treatments are not connected, they cannot be 
compared. Connectedness is typically tested by visual inspection, however this 
is time consuming when there are many separate networks representing dif-
ferent outcomes, subgroups, and scenarios, and also prone to error, especially 
in large networks . Path finding algorithms can be used to automate testing for 
connectedness, but these are slow and inefficient. We present a fast and sim-
ple approach to test connectedness. MethOds: Our method constructs a sym-
metric square matrix, called the direct connection matrix, with the number of 
rows and columns equal to the number of treatments in the network. We fill 
this matrix with ones where treatments of the corresponding row and column 
have been compared in a trial, and zeros otherwise. The diagonal is filled with 
ones. Exponentiation of the matrix to the number of treatments, minus one, 
gives the indirect connection matrix. Non-zero entries of this final matrix rep-
resent treatment combinations that can be compared using available evidence, 
and vice versa. This test is easy to implement in software and can be conducted 
rapidly. We prove the validity of the method mathematically and illustrate with 
application to a network of anticoagulants for the prevention of stroke in atrial 
fibrillation. cOnclusiOns: We have developed a simple and rapid test of con-
nectedness of networks that is easy to automate and can be applied to any network 
meta-analysis.
